Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.
暂无分享,去创建一个
Steven J. M. Jones | Benjamin J. Raphael | Mark D. M. Leiserson | Angela N. Brooks | Richard A. Moore | Lisle E. Mose | Caleb F. Davis | D. Haussler | S. Gabriel | M. Gerstein | R. Gibbs | P. Spellman | M. Meyerson | J. Cheville | C. Perou | J. Weinstein | G. Mills | D. Muzny | L. Lewis | A. Hawes | C. Kovar | D. Wheeler | C. Sougnez | R. Beroukhim | S. Carter | P. Laird | D. Weisenberger | S. Baylin | D. Hayes | K. Hoadley | S. Balu | Yan Shi | Junyuan Wu | R. Penny | S. Morris | J. Schein | M. Wilkerson | M. Marra | N. Thiessen | Y. Butterfield | R. Holt | A. G. Robertson | Angela Tam | P. Mieczkowski | Hui Shen | J. Parker | W. Linehan | R. Srinivasan | L. Schmidt | G. Saksena | S. Signoretti | T. Ho | A. Mungall | Adrian Ally | M. Balasundaram | Eric Chuah | Noreen Dhalla | R. Guin | Michael Mayo | R. Akbani | J. Bowen | J. Gastier-Foster | T. Lichtenberg | L. Wise | John A. Demchok | Margi Sheth | H. Sofia | Liming Yang | S. Schumacher | V. Reuter | A. Hakimi | J. Hsieh | W. Rathmell | R. Thompson | C. Creighton | P. Tamboli | C. Ricketts | Donna Morton | H. Doddapaneni | W. Hale | D. Kalra | A. Cherniack | Payal Sipahimalani | R. Carlsen | J. Auman | Donghui Tan | Corbin D. Jones | S. Jefferys | T. Bodenheimer | A. Hoyle | J. Simons | Phillip H. Lai | M. Bootwalla | Yiling Lu | S. Fei | C. Shelton | J. Gardner | M. Sherman | D. Mallery | J. Paulauskis | K. Burnett | T. Choueiri | Erin E. Curley | S. Tickoo | L. Thorne | L. Boice | C. Vocke | M. Merino | B. Czerniak | J. Boyd | M. Iacocca | N. Petrelli | L. Huelsenbeck-Dill | B. Rabeno | J. Myers | Julie Bergsten | J. Eckman | Jodi Harr | Kelinda Tucker | L. A. Zach | R. Dhir | J. Maranchie | J. Nelson | A. Parwani | M. Blute | T. Pihl | Brenda Ayala | J. Baboud | Zhining Wang | R. Tarnuzzer | J. Zhang | B. Shuch | Yingbei Chen | Yao Fu | A. Sethi | Jingchun Zhu | E. Reznik | B. Krishnan | William Y. Kim | A. Godwin | J. Drummond | Jun Li | S. Meng | P. Yena | Min Wang | T. Skelly | J. Bartlett | R. Bowlby | Ina Felau | C. Hutter | J. Zenklusen | Sudha Chudamani | Jia Liu | Laxmi Lolla | R. Naresh | Qiang Sun | Yunhu Wan | Ye Wu | Han Liang | Shiyun Ling | Pavana Anur | Myron Peto | Denise Brooks | K. Kasaian | Yussanne Ma | S. Sadeghi | Tina Wong | Steven E Schumacher | D. J. Van Den Berg | J. Roach | Matthew G. Soloway | Umadevi Veluvolu | K. Covington | E. Shinbrot | Liu Xi | D. Crain | Kevin R Lau | E. Thompson | M. Gerken | Kristen Leraas | N. Ramirez | E. Zmuda | M. Ittmann | E. Castle | M. Stanton | Meijuan Huang | C. Buhay | Fengju Chen | C. Shelley | A. Clarke | Bradley A. Murray | Amie Radenbaugh | Monique Albert | I. Alexopoulou | J. Engel | J. Parfitt | A. Salner | Jason Bedford | K. R. Mills Shaw | B. Jacobs | S. Brooks | R. Bollag | P. Weinberger | S. Bastacky | B. Davies | R. Hrebinko | G. Thomas | R. Zuna | Jane H. Zhou | Somak Roy | N. Barnabas | J. Slaton | H. Chao | S. McMeekin | A. A. A. Al Mamun | S. Haake | D. Bottaro | L. Albiges | W. Shelton | Melissa Avedon | Tracie Santos | M. Dahdouli | N. Dewal | Jie Li | J. Andersen | April DeVolk | Laura Dike | M. Lobis | C. Winemiller | Kenna R. Mills Shaw | W. T. Shelton | R. Moore | E. Chuah | K. Leraas | Ying-bei Chen | Jay Bowen | Walker Hale | Jeremiah J. Andersen | T. Santos | D. Muzny | Steven J. M. Jones | J. Parker | A. G. Robertson | R. Thompson | Tara J. Skelly | M. Merino | Rehan Akbani | Moiz Bootwalla | Abu Amar M Al Mamun | A. A. M. Al Mamun
[1] Lisa N Kinch,et al. Spectrum of diverse genomic alterations define non–clear cell renal carcinoma subtypes , 2014, Nature Genetics.
[2] Hui Yang,et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. , 2012, Genes & development.
[3] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[4] Soroush Rais-Bahrami,et al. Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers , 2014, Nature Reviews Urology.
[5] Benjamin J. Raphael,et al. Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.
[6] Steven J. M. Jones,et al. Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.
[7] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[8] A. Jaiswal,et al. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[9] Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.
[10] W Marston Linehan,et al. Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics , 2012, Genome research.
[11] W. Linehan,et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas , 1999, Oncogene.
[12] B. Delahunt,et al. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[13] I. Varela,et al. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution , 2015, Nature Communications.
[14] W. Linehan,et al. The genetic basis of kidney cancer: a metabolic disease , 2010, Nature Reviews Urology.
[15] C. Ball,et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.
[16] R. Wilson,et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.
[17] Bin Tean Teh,et al. Nanoscale chromatin profiling of gastric adenocarcinoma reveals cancer-associated cryptic promoters and somatically acquired regulatory elements , 2014, Nature Communications.
[18] H. Moch,et al. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. , 1998, The American journal of pathology.
[19] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[20] P. Choyke,et al. Hereditary papillary renal cell carcinoma. , 1994, The Journal of urology.
[21] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[22] Karl J. Dykema,et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. , 2013, Cancer research.
[23] Peter W. Laird,et al. Interplay between the Cancer Genome and Epigenome , 2013, Cell.
[24] P. Choyke,et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. , 2007, The Journal of urology.
[25] W Marston Linehan,et al. Molecular Pathways: Fumarate Hydratase-Deficient Kidney Cancer—Targeting the Warburg Effect in Cancer , 2013, Clinical Cancer Research.
[26] A. Lane,et al. Metabolic Reprogramming for Producing Energy and Reducing Power in Fumarate Hydratase Null Cells from Hereditary Leiomyomatosis Renal Cell Carcinoma , 2013, PloS one.
[27] G. Halder,et al. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment , 2013, Nature Reviews Drug Discovery.
[28] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[29] L. Aaltonen,et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[30] M. Sporn,et al. NRF2 and cancer: the good, the bad and the importance of context , 2012, Nature Reviews Cancer.
[31] W. Linehan,et al. Fumarate Hydratase Deficiency in Renal Cancer Induces Glycolytic Addiction and Hypoxia-Inducible Transcription Factor 1α Stabilization by Glucose-Dependent Generation of Reactive Oxygen Species , 2009, Molecular and Cellular Biology.
[32] H. Gan,et al. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered , 2013, The FEBS journal.
[33] K. Rex,et al. Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors. , 2009, Bioorganic & medicinal chemistry letters.
[34] Vladimir Valera Romero,et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. , 2011, Cancer cell.
[35] A. Paetau,et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer , 2002, Nature Genetics.
[36] James B. Mitchell,et al. Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer. , 2014, Cancer cell.
[37] Ximing J. Yang,et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. , 2011, Cancer cell.
[38] P. Choyke,et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. , 1998, Cancer research.
[39] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[40] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[41] Keith T Flaherty,et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.